stoxline Quote Chart Rank Option Currency Glossary
Bluejay Diagnostics, Inc. (BJDX)
3.26  0.1 (3.16%)    12-08 15:55
Open: 3.15
High: 3.312
Volume: 4,189
Pre. Close: 3.16
Low: 3.13
Market Cap: 4(M)
Technical analysis
2023-12-08 4:41:57 PM
Short term     
Mid term     
Targets 6-month :  4.07 1-year :  4.49
Resists First :  3.49 Second :  3.84
Pivot price 3.19
Supports First :  2.91 Second :  2.42
MAs MA(5) :  3.19 MA(20) :  3.22
MA(100) :  4.86 MA(250) :  6.82
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  24.9 D(3) :  29.6
RSI RSI(14): 46.8
52-week High :  17.6 Low :  2.9
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ BJDX ] has closed below upper band by 36.2%. Bollinger Bands are 82.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 36 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 3.32 - 3.33 3.33 - 3.34
Low: 3.1 - 3.11 3.11 - 3.13
Close: 3.24 - 3.26 3.26 - 3.28
Company Description

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Headline News

Thu, 09 Nov 2023
Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results - Yahoo Finance

Wed, 27 Sep 2023
Should You Hold Bluejay Diagnostics Inc (BJDX) Stock Wednesday Morning? - InvestorsObserver

Wed, 20 Sep 2023
Where Will Bluejay Diagnostics Inc (BJDX) Stock Go Next After It Is Higher By 44.66% in a Week? - InvestorsObserver

Wed, 20 Sep 2023
What's Going On With Bluejay Diagnostics Stock Today? - Bluejay Diagnostics (NASDAQ:BJDX) - Benzinga

Fri, 28 Jul 2023
What's Going On With BlueJay Diagnostics Stock? - Bluejay Diagnostics (NASDAQ:BJDX) - Benzinga

Wed, 26 Jul 2023
Is Bluejay Diagnostics Inc (BJDX) a Good Buy in the Medical Devices Industry? - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Medical Devices
Shares Out 1 (M)
Shares Float 1 (M)
Held by Insiders 44.3 (%)
Held by Institutions 0.6 (%)
Shares Short 3 (K)
Shares Short P.Month 21 (K)
Stock Financials
EPS -9.65
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.21
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -54.2 %
Return on Equity (ttm) -105.6 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0.03
Sales Per Share 0
EBITDA (p.s.) -7.84
Qtrly Earnings Growth 0 %
Operating Cash Flow -8 (M)
Levered Free Cash Flow -6 (M)
Stock Valuations
PE Ratio -0.34
PEG Ratio 0
Price to Book value 0.77
Price to Sales 0
Price to Cash Flow -0.48
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android